Galecto Inc
GLTO2.870USD
0.000
終値 09/19, 16:00（ET）15分遅れの株価
3.80M時価総額
損失額直近12ヶ月PER
詳細情報 Galecto Inc 企業名
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
企業情報
企業コードGLTO
会社名Galecto Inc
上場日Oct 29, 2020
最高経営責任者「CEO」Dr. Hans T. Schambye, M.D., Ph.D.
従業員数5
証券種類Ordinary Share
決算期末Oct 29
本社所在地75 State Street
都市BOSTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02109
電話番号14570705210
ウェブサイトhttps://galecto.com/
企業コードGLTO
上場日Oct 29, 2020
最高経営責任者「CEO」Dr. Hans T. Schambye, M.D., Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Amy Wechsler, M.D.
Dr. Amy Wechsler, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David M. Shapiro, M.D.
Dr. David M. Shapiro, M.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Amy Wechsler, M.D.
Dr. Amy Wechsler, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, Aug 15
更新時刻: Fri, Aug 15
株主統計
種類
株主統計
株主統計
比率
Novo Holdings A/S
7.54%
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.10%
Susquehanna International Group, LLP
1.03%
他の
84.94%
株主統計
株主統計
比率
Novo Holdings A/S
7.54%
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.10%
Susquehanna International Group, LLP
1.03%
他の
84.94%
種類
株主統計
比率
Venture Capital
9.77%
Individual Investor
3.68%
Investment Advisor
1.68%
Hedge Fund
1.17%
Investment Advisor/Hedge Fund
0.70%
Research Firm
0.10%
他の
82.90%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
2023Q2
66
515.37K
50.18%
-71.94K
2023Q1
67
465.15K
45.46%
-174.31K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Novo Holdings A/S
99.91K
7.56%
--
--
Mar 31, 2025
Goldfischer (Carl S)
41.96K
3.17%
+1.00
+0.00%
Apr 15, 2025
Danmarks Eksport- og Investeringsfond
29.52K
2.23%
-29.52K
-50.00%
Sep 30, 2024
Renaissance Technologies LLC
15.34K
1.16%
+300.00
+1.99%
Mar 31, 2025
Susquehanna International Group, LLP
10.72K
0.81%
+10.72K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
10.89K
0.82%
+1.93K
+21.48%
May 31, 2025
The Vanguard Group, Inc.
8.85K
0.67%
--
--
May 31, 2025
Schambye (Hans T.)
3.40K
0.26%
+1.00
+0.03%
Apr 15, 2025
UBS Financial Services, Inc.
285.00
0.02%
-12.18K
-97.71%
Mar 31, 2025
Winslow (Garrett)
1.01K
0.08%
--
--
Apr 15, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
日付
種類
比率
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
